Announcements Trials
Browse Landscape

Status

Completed 257Terminated 99Unknown 62Recruiting 46Active not recruiting 26Withdrawn 24Not yet recruiting 10No longer available 3Suspended 2Enrolling by invitation 2Available 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Breast Neoplasms 58Neoplasms 52Colorectal Neoplasms 32Prostatic Neoplasms 29Lung Neoplasms 21Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 16Carcinoma, Hepatocellular 16Uterine Cervical Neoplasms 13Anxiety Disorders 13Colonic Neoplasms 11Brain Neoplasms 11Pancreatic Neoplasms 10Lymphoma, Follicular 9Leukemia, Myeloid, Acute 8Head and Neck Neoplasms 8Barrett Esophagus 8Urinary Bladder Neoplasms 7Rectal Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Disease 7Diabetes Mellitus 7Cholangiocarcinoma 7Sarcoma 6Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Pain 6Ovarian Neoplasms 6Motor Activity 6

Interventions

olverembatinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enrolling by invitation × OTHER × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT07383298 2026-02-03

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Peking University People's Hospital

Enrolling by invitation
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06646978 2024-10-17

K2SPIRIT

Poitiers University Hospital

Enrolling by invitation
787 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡